The Australian Immunisation Handbook 10th Edition 2013

contains 4 µg each of serogroups A, C, W 135 and Y polysaccharides
conjugated with a total of approximately 48 µg of a diphtheria toxoid
protein.
• Menveo – CSL Limited/Novartis Vaccines and Diagnostics Pty
Ltd (meningococcal serogroups A, C, W 135 , Y–CRM 197 conjugate).
Lyophilised powder containing serogroup A (MenA) in a monodose
vial with a pre-filled syringe or vial containing serogroups C, W 135 and
Y (MenCWY) in saline suspension. Each 0.5 mL reconstituted dose
contains 10 µg of serogroup A and 5 µg each of serogroups C, W 135
and Y oligosaccharides individually conjugated with up to 33.3 µg of
non-toxic C. diphtheriae CRM 197 protein; sucrose.
All conjugate vaccines induce immunity within 10 to 14 days of administration.
MenCCVs confer protection only against serogroup C disease. 4vMenCVs will
provide protection against four serogroups of meningococci: serogroups A, C,
W and Y. Neither MenCCV nor 4vMenCV will provide protection against
135
serogroup B meningococcal disease.
MenCCVs have been used in an infant schedule in many countries, including
Australia. 11-13,17-19 The vaccine effectiveness following 1 dose of MenCCV has
been estimated to range from 83 to 100%. 13,17 There has been a sustained decline
in serogroup C meningococcal disease, which has also been observed in age
groups not targeted in vaccination programs, both in Australia and overseas. 11,14
Duration of immunity is still uncertain. However, current serogroup C
meningococcal disease epidemiology in Australia suggests ongoing protection in
those groups previously vaccinated. 11
Hib-MenCCV can be administered where a booster dose of H. influenzae
type b and primary vaccination for meningococcal serogroup C is required.
The immunogenicity and safety of Hib-MenCCV as a booster dose has been
demonstrated in clinical trials and in the United Kingdom, where this vaccine is
now administered as part of the infant schedule. 20-25
Several clinical trials have demonstrated the immunogenicity of 4vMenCV,
with human serum bactericidal assay titres of ≥1:4 reported in adolescents and
young adults. 26-28 There have been a number of studies examining 4vMenCV in
children. 29-31 All studies indicated that 4vMenCVs were safe and immunogenic in
both infants and children. 29-33 Menveo has demonstrated superiority to Menactra
in serum bactericidal assays to serogroups A, W and Y (and variably also to
135
serogroup C); however, the clinical relevance of this is currently unknown. 27,34-36
286 The Australian Immunisation Handbook 10th edition